CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

Journal of Clinical Investigation

Volumn 103, Issue 9, 1999, Pages 1243-1252

  Abrams, Judith R ^a   Lebwohl, Mark G ^b   Guzzo, Cynthia A ^c   Jegasothy, Brian V ^d   Goldfarb, Michael T ^e   Goffe, Bernard S ^f   Menter, Alan ^g   Lowe, Nicholas J ^h   Krueger, Gerald ⁱ   Brown, Michael J ^a   Weiner, Russell S ^a   Birkhofer, Martin J ^a   Warner, Garvin L ^j   Berry, Karen K ^a   Linsley, Peter S ^k   Krueger, James G ^l   Ochs, Hans D ^m   Kelley, Susan L ^a   Kang, Sewon ^e  

^a BRISTOL MYERS SQUIBB   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f Tampere University   (United States)

^g BAYLOR HEALTH CARE SYSTEM   (United States)

^h Clinical Research Specialists   (United States)

ⁱ UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^j PFIZER INC   (United States)

^k ROSETTA INPHARMATICS   (United States)

^l ROCKEFELLER UNIVERSITY   (United States)

^m UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CYTOTOXIC LYMPHOCYTE; HUMAN; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS VULGARIS; SIGNAL TRANSDUCTION;

EID: 0033135564     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI5857     Document Type: Article

References (50)

1. Greaves, M.W., and Weinstein, G.D. 1995. Treatment of psoriasis. N. Engl. J. Med. 332:581-588.
2. Demidem, A., Taylor, R., Grammer, S.F., and Streilein, J.W. 1991. T-lymphocyte-activating properties of epidermal antigen-presenting cells from normal and psoriatic skin: evidence that psoriatic epidermal antigen-presenting cells resemble cultured normal Langerhans cells. J. Invest. Dermatol. 97:454-460.
3. Chang, E.Y., et al. 1992. T-cell activation is potentiated by cytokines released by lesional psoriatic, but not normal epidermis. Arch. Dermatol. 128:1479-1485.
4. Strange, P., et al. 1993. T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J. Invest. Dermatol. 101:695-700.
5. Bata-Csorgo, Z., Hammerberg, C., Voorhees, J.J., and Cooper, K.D. 1995. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. J. Clin. Invest. 95:317-327.
6. Bachelez, H., et al. 1998. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J. Autoimmun. 11:53-62.
7. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1:442-447.
8. Mueller, W., and Herrman, B. 1979. Cyclosporin A for psoriasis. N. Engl. J. Med. 301:555.
9. Mueller, D.L., Jenkins, M.K., and Schwartz, R.H. 1989. Clonal expansion versus functional inactivation: a costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7:445-480.
10. Linsley, P.S., et al. 1991. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173:721-730.
11. Linsley, P.S., et al. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174:561-569.
12. Sayegh, M.H., and Turka, L.A. 1998. The role of T-cell costimulatory activation pathways in transplant rejection. N. Engl. J. Med. 338:1813-1821.
13. Lenschow, D.J., et al. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science. 257:789-792.
14. Lin, H., et al. 1993. Long-term acceptance of major histocompatability complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 178:1801-1806.
15. Sayegh, M.H., et al. 1995. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 181:1869-1874.
16. Kirk, A.D., et al. 1997. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA. 94:8789-8794.
17. Reiser, H., and Stadecker, M.D. 1996. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N. Engl. J. Med. 335:1369-1377.
18. Finck, B.K., Linsley, P.S., and Wofsy, D. 1994. Treatment of murine lupus with CTLA4Ig. Science. 265:1225-1227.
19. Cross, A.H., et al. 1995. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95:2783-2789.
20. Webb, L.M.C., Walmsley, M.J., and Feldmann, M. 1996. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26:2320-2328.
21. Larsen, C.P., et al. 1994. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J. Immunol. 152:5208-5219.
22. Symington, F.W., Brady, W., and Linsley, P.S. 1993. Expression and function of B7 on human epidermal Langerhans cells. J. Immunol. 150:1286-1295.
23. Nestle, F.O., Turka, L.A., and Nickoloff, B.J. 1994. Characterization of detmal dendritic cells in psoriasis. J. Clin. Invest. 94:202-209.
24. Jones, E.L., Epinette, W.W., Hackney, V.C., Menendez, L., and Frost, P. 1975. Treatment of psoriasis with oral mycophenolic acid. J. Invest. Dermatol. 65:537-542.
25. Srinivas, N.R., et al. 1996. Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. J. Pharm. Sci. 85:1-4.
26. Ochs, H.D., Davis, S.D., and Wedgwood, R.J. 1971. Immunologic responses to bacteriophage φX174 in immunodeficiency diseases. J. Clin. Invest. 50:2559-2568.
27. Linsley, P.S., et al. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 257:792-795.
28. Vallat, V.P., et al. 1994. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J. Exp. Med. 180:283-296.
29. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S.A. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol. 119:493-501.
30. Agresti, A., Mehta, C.R., and Patel, N.R. 1990. Exact inference for contingency tables with ordered categories. J. Am. Star. Assoc. 85:453-458.
31. Hotchin, N.A., Gandarillas, A., and Watt, F.M. 1995. Regulation of cell surface β1 integrin levels during keratinocyte terminal differentiation. J. Cell Biol. 128:1209-1219.
32. Gerdes, J., et al. 1984. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133:1710-1715.
33. Ozawa, M., et al. 1999. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J. Exp. Med. 189:711-718.
34. Cabrian, K.M., et al. 1996. Suppression of T-cell-dependent immune responses in monkeys by CTLA4Ig. Transplant. Proc. 28:3261-3262.
35. + T cells and defective antibody production in vivo. J. Exp. Med. 179:809-817.
36. L. Immunity. 3:87-98.
37. Van Parijs, L., Ibraghimov, A., and Abbas, A.K. 1996. The roles of costimulation and FAS in T cell apoptosis and peripheral tolerance. Immunity. 4:321-328.
38. Austrup, F., et al. 1997. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature. 385:81-83.
39. Chin, Y.-H., Falanga, V., Taylor, J.R., Cai, J.-P., and Bax, J. 1990. Adherence of human helper/memory T-cell subsets to psoriatic dermal endothelium. J. Invest. Dermatol. 94:413-417.
40. Dunn, D., et al. 1993. T cell receptor Vβ expression in normal human skin. Proc. Natl. Acad. Sci. USA. 90:1267-1271.
41. + T cells in psoriatic lesions preferentially use T-cell receptor Vβ3 and/or Vβ13.1 genes. Proc. Natl. Acad. Sci. USA. 91:9282-9286.
42. Gottlieb, A.B., et al. 1992. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J. Invest. Dermatol. 98:302-309.
43. Viola, A., and Lanzavecchia, A. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science. 273:104-106.
44. Iezzi, G., Karjalainen, K., and Lanzavecchia, A. 1998. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity. 8:89-95.
45. Greene, J.L., et al. 1996. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. 271:26762-26771.
46. Krummel, M.F., and Allison, J.P. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533-2540.
47. Tivol, E.A., et al. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 3:541-547.
48. Tivol, E.A., et al. 1997. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J. Immunol. 158:5091-5094.
49. Mandelbrot, D.A., McAdam, A.J., and Sharpe, A.H. 1999. B7-1 or B7-2 is required to produce the lymphoproliferarive phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J. Exp. Med. 189:435-440.
50. Perez, V.L., et al. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 6:411-417.